| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| July 23rd, 2004 | 21 | Yes |
Popular Name: Procyclidine hydrochloride Procyclidine hydrochloride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 1508-76-5 , 1508-76-5, 77-37-2 [procy , 1508-76-5, 77-37-2 [procyclidine] , 32381-60-5 , 77-37-2 , [1508-76-5]
1-Cyclohexyl-1-phenyl-3-(1-pyrrolidinyl)-1-propanol
1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol
1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol
1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol; Procyclidine; Tricyclamol
1-Pyrrolidinepropanol, .alpha.-cyclohexyl-.alpha.-phenyl-
1-PYRROLIDINEPROPANOL, alpha-CYCLOHEXYL-alpha-PHENYL-
1508-76-5; D00782; Kemadrin (TN); Procyclidine hydrochloride (USP)
1508-76-5; Prestwick_125; Procyclidine hydrochloride
5-20-01-00250 (Beilstein Handbook Reference)
77-37-2; D08425; Procyclidine (INN)
CPD000058821; Kemadrin; SAM002564231
CPD000058821; Procyclidine hydrochloride; SAM002564231
INN); Procyclidine Hydrochloride (FDA
Prociclidina [INN-Spanish];Procyclidinum [INN-Latin]
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 4.33 | 9.71 | -35.38 | 2 | 2 | 1 | 25 | 288.455 | 5 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 9.84e-03 g/l | DrugBank-approved |
| Therapy | anticholinergic | SMDC Iconix |
| Patent Database Links | EP1649857; EP1815846; EP1829527; EP1829528; US2007190043; US2007225379; WO2006019673; WO2006091697 | ChEBI |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : P-7206; NCC_SUPPLIER_SAMPLE_COMMENTS : WHITE POWDER; 1 hydrogen chloride | NIH Clinical Collection via PubChem |
| Target | Others | Selleck Chemicals |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: P-7206; SALT: 1 hydrogen chloride; SUPPLIER_COMMENTS: WHITE POWDER | NIH Clinical Collection via PubChem |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| NMD3A-2-E | Glutamate [NMDA] Receptor Subunit 3A (cluster #2 Of 6), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| NMD3B-2-E | Glutamate [NMDA] Receptor Subunit 3B (cluster #2 Of 6), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE1-2-E | Glutamate [NMDA] Receptor Subunit Epsilon 1 (cluster #2 Of 5), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE2-1-E | Glutamate [NMDA] Receptor Subunit Epsilon 2 (cluster #1 Of 5), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE3-1-E | Glutamate [NMDA] Receptor Subunit Epsilon 3 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE4-2-E | Glutamate [NMDA] Receptor Subunit Epsilon 4 (cluster #2 Of 6), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| NMDZ1-2-E | Glutamate (NMDA) Receptor Subunit Zeta 1 (cluster #2 Of 6), Eukaryotic | Eukaryotes | 1700 | 0.38 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| NMDZ1_HUMAN | Q05586 | Glutamate (NMDA) Receptor Subunit Zeta 1, Human | 1700 | 0.38 | Binding ≤ 10μM |
| NMD3A_HUMAN | Q8TCU5 | Glutamate [NMDA] Receptor Subunit 3A, Human | 1700 | 0.38 | Binding ≤ 10μM |
| NMD3B_HUMAN | O60391 | Glutamate [NMDA] Receptor Subunit 3B, Human | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE1_HUMAN | Q12879 | Glutamate [NMDA] Receptor Subunit Epsilon 1, Human | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE2_HUMAN | Q13224 | Glutamate [NMDA] Receptor Subunit Epsilon 2, Human | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE3_HUMAN | Q14957 | Glutamate [NMDA] Receptor Subunit Epsilon 3, Human | 1700 | 0.38 | Binding ≤ 10μM |
| NMDE4_HUMAN | O15399 | Glutamate [NMDA] Receptor Subunit Epsilon 4, Human | 1700 | 0.38 | Binding ≤ 10μM |
| Description | Species |
|---|---|
| CREB phosphorylation through the activation of CaMKII | |
| EPHB-mediated forward signaling | |
| Ras activation uopn Ca2+ infux through NMDA receptor | |
| Unblocking of NMDA receptor, glutamate binding and activation |